{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:42:29Z","timestamp":1777480949060,"version":"3.51.4"},"reference-count":43,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Radiolabeled antibody fragments present a promising opportunity as theranostic agents, offering distinct advantages over whole antibodies. In this study, the authors investigate the potential of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DTPA-F(ab\u2032)\n                      <jats:sub>2<\/jats:sub>\n                      -pertuzumab as a theranostic agent for precise targeting of human epidermal growth factor receptor 2 (HER2)-positive cancers. Additionally, the authors aim to quantitatively assess the binding synergism in the presence of cold trastuzumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      F(ab\u2032)\n                      <jats:sub>2<\/jats:sub>\n                      -pertuzumab was prepared by pepsin digestion and conjugated with a bifunctional chelator. The immunoconjugate was radiolabeled with\n                      <jats:sup>177<\/jats:sup>\n                      Lu and characterized by chromatography techniques. Binding parameters (affinity, specificity, and immunoreactivity) and cellular binding enhancement studies were evaluated in HER2-overexpressing and triple-negative cell lines. The\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      enhancement in tumor uptake of the radiolabeled immunoformulation was assessed in severe combined immunodeficient (SCID) mice bearing tumors, both in the presence and absence of unlabeled trastuzumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The formulation of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DTPA-F(ab\u2032)\n                      <jats:sub>2<\/jats:sub>\n                      -pertuzumab could be prepared in high yields and with consistent radiochemical purity, ensuring reproducibility. Comprehensive\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      evaluation studies confirmed high specificity and immunoreactivity of the formulation toward HER2 receptors. Binding synergism of radiolabeled pertuzumab fragments in the presence of trastuzumab to HER2 receptors was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      The radioformulation of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DTPA-F(ab\u2032)\n                      <jats:sub>2<\/jats:sub>\n                      -pertuzumab holds great promise as a targeted approach for addressing HER2-positive cancers. A potentially effective strategy to amplify therapeutic efficacy involves dual epitope targeting by combining radiolabeled pertuzumab with cold trastuzumab.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cbr.2023.0108","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T13:45:21Z","timestamp":1708091121000},"page":"64-74","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of\n                    <sup>177<\/sup>\n                    Lu-Labeled Pertuzumab F(ab\u2032)\n                    <sub>2<\/sub>\n                    Fragments for HER2-Positive Cancer Targeting: A Comparative\n                    <i>In Vitro<\/i>\n                    and\n                    <i>In Vivo<\/i>\n                    Study"],"prefix":"10.1177","volume":"39","author":[{"given":"Rohit","family":"Sharma","sequence":"first","affiliation":[{"name":"Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India."},{"name":"Department of Life Sciences, Homi Bhabha National Institute, Mumbai, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3068-1890","authenticated-orcid":false,"given":"Archana","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India."},{"name":"Department of Life Sciences, Homi Bhabha National Institute, Mumbai, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haladhar Dev","family":"Sarma","sequence":"additional","affiliation":[{"name":"Radiation Biology &amp; Health Sciences Division, Bhabha Atomic Research Centre (BARC), Mumbai, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"e_1_3_6_2_2","unstructured":"Ferlay J Ervik M Lam F et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer: Lyon; 2020. Available from: https:\/\/gco.iarc.fr\/today [Last accessed: January 2024]."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-18-ASOCCO"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0230"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(89)90343-1"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.78271"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0798-2"},{"issue":"1","key":"e_1_3_6_9_2","first-page":"21","article-title":"Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it","volume":"10","author":"Luque-Cabal M","year":"2016","unstructured":"Luque-Cabal M, , Garc\u00eda-Teijido P, , Fern\u00e1ndez-P\u00e9rez Y, et al. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol, 2016; 10(Suppl 1):21\u201330.","journal-title":"Clin Med Insights Oncol"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3856"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0043-2"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-307"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155636"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052122"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.3063"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30500"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92460-0"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3663-y"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071338"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2888"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00775"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.07.029"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03027399"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.12.005"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/15368590252917593"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2004.08.003"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1385\/0-89603-268-X:9"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc00016a014"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2019.04.002"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90435-6"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp500323d"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.141.1.208"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(82)90272-7"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/2191-219X-1-1"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2019.3056"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100342"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/npjbcancer.2015.12"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82812-1"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2008.04.012"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0704"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01287"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1018"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0044"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2023.0108","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2023.0108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2023.0108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:16Z","timestamp":1777385476000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2023.0108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1089\/cbr.2023.0108"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2023.0108","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}